At 24 months of follow-up, shorter PFS was observed in patients with advanced tumor stage (34.4% versus 83.3%, P= 0.03) and XPD c.934AA genotype (10.0% versus 41.2%, P= 0.02) (Figure 1C); a shorter OS was also observed in patients with advanced tumor stage (38.4% versus 100.0%, P= 0.02) and XPD c.934AA genotype (10.0% versus 46.9%, P= 0.02) (Figure 1D) at this time (Kaplan-Meier estimates). This evidence concerns the gene ERCC2 and neoplasm.